13 completed, 3 active not recruiting, 3 withdrawn, 2 recruiting. 11 Phase 1, 11 Phase 2, 2 Phase 3.
Follow imetelstat: new trials by email Literature Review of imetelstat trials Research Report on imetelstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms Imetelstat - Phase II, Imetelstat | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-10-08 | 2026-04-24 |
| Imetelstat Combinations in Relapsed AML Imetelstat, Azacitidine, Venetoclax - Relapsed Acute Myeloid Leukemia | Phase 1 | Recruiting | Douglas Tremblay | 36 | 2026-01-02 | 2026-04-22 |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome | Phase 1 | Recruiting | Children's Oncology Group | 36 | 2025-02-04 | 2026-08-25 |
| Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy Imetelstat sodium - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Completed | GCP-Service International West GmbH | 46 | 2023-06-05 | 2026-10-02 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis Imetelstat sodium, Ruxolitinib - Myelofibrosis | Phase 1 | Active not recruiting | Geron Corporation | 30 | 2022-05-04 | 2026-08-26 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Active not recruiting | Geron Corporation | 327 | 2021-04-12 | 2026-07-08 |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Imetelstat Sodium, Placebo - Myelodysplastic Syndromes | Phase 2 / Phase 3 | Active not recruiting | Geron Corporation | 289 | 2016-01-12 | 2026-07-17 |
| Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg - Myelofibrosis | Phase 2 | Completed | Geron Corporation | 107 | 2015-08-28 | 2021-09-14 |
| Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Imetelstat Sodium, Laboratory Biomarker Analysis - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Withdrawn | Children's Oncology Group | 2014-06-30 | 2018-08-07 | |
| Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma Imetelstat - Neuroblastoma | Phase 1 | Withdrawn | NCIC Clinical Trials Group | 2013-07-30 | 2020-09-21 | |
| Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors imetelstat sodium - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 2 | Terminated | Pediatric Brain Tumor Consortium | 43 | 2013-03-01 | 2018-07-20 |
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis Imetelstat - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Geron Corporation | 80 | 2012-10-29 | 2021-09-21 |
| Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma Imetelstat - Solid Tumors, Lymphoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2012-03-01 | 2012-11-21 | |
| Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma imetelstat sodium, laboratory biomarker analysis, pharmacological study - Brain and Central Nervous System Tumors, Lymphoma | Phase 1 | Completed | Children's Oncology Group | 34 | 2011-05-01 | 2014-01-30 |
| A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer GRN163L in combination with trastuzumab - Breast Neoplasms | Phase 1 | Completed | Indiana University | 10 | 2011-01-01 | 2015-10-27 |
| Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Imetelstat - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Completed | Geron Corporation | 20 | 2010-12-01 | 2016-01-26 |
| Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg) - Multiple Myeloma | Phase 2 | Completed | Geron Corporation | 13 | 2010-11-01 | 2026-06-17 |
| Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer Imetelstat sodium, Bevacizumab, Paclitaxel - Locally Recurrent or Metastatic Breast Cancer | Phase 2 | Completed | Geron Corporation | 166 | 2010-11-01 | 2016-01-26 |
| Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) imetelstat, Bevacizumab - Non-small Cell Lung Cancer | Phase 2 | Completed | Geron Corporation | 116 | 2010-05-01 | 2016-01-26 |
| Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma Imetelstat Sodium (GRN163L) - Multiple Myeloma | Phase 1 | Completed | Geron Corporation | 40 | 2008-07-01 | 2015-12-24 |
Showing 20 of 24. Sign in to see all of them.
Recurrence (6) · Myelodysplastic Syndromes (4) · Primary Myelofibrosis (4) · Multiple Myeloma (3) · Neoplasms, Plasma Cell (3) · Astrocytoma (2) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Glioblastoma (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Myeloproliferative Disorders (2) · Neuroblastoma (2) · Oligodendroglioma (2) · Brain Stem Neoplasms (1)
Geron Corporation (14) · Children's Oncology Group (3) · Douglas Tremblay (1) · GCP-Service International West GmbH (1) · Indiana University (1) · M.D. Anderson Cancer Center (1) · NCIC Clinical Trials Group (1) · National Cancer Institute (NCI) (1) · Pediatric Brain Tumor Consortium (1)
United States (19) · Canada (6) · Germany (6) · France (4) · Belgium (3) · Israel (3) · Italy (3) · South Korea (3) · Spain (3) · United Kingdom (3) · Australia (2) · Poland (2) · Russia (2) · Switzerland (2) · Taiwan (2)
Joe Eid (2) · Kathy Miller, MD (2) · Alexandra M Stevens (1) · Bravo G Montalban, MD (1) · Carol Ann Huff, M.D. (1) · Douglas Tremblay, MD (1) · Joan Schiller, MD (1) · John Mascarenhas, MD (1) · Maryam Fouladi (1) · Michelle Mudge-Riley, DO (1) · Patrick A. Thompson, MD (1) · Patrick Thompson (1) · Stephen Kelsey, MD (1) · Steve Kelsey, MD (1)
PMID 26332545, PMID 26332546, PMID 32732354, PMID 33108243, PMID 34138638, PMID 35510486, PMID 38048786, PMID 41135032, PMID 41568521
2015 (2), 2023 (1), U01CA081457 (1), U10CA098543 (1), UM1CA228823 (1)